Advertisement

Tumor Biology

, Volume 36, Issue 10, pp 7775–7787 | Cite as

The elevated pretreatment platelet-to-lymphocyte ratio predicts poor outcome in nasopharyngeal carcinoma patients

  • Rou Jiang
  • Xiong Zou
  • Wen Hu
  • Yu-Ying Fan
  • Yue Yan
  • Meng-Xia Zhang
  • Rui You
  • Rui Sun
  • Dong-Hua Luo
  • Qiu-Yan Chen
  • Pei-Yu Huang
  • Yi-Jun Hua
  • Ling Guo
  • Ming-Yuan Chen
Research Article

Abstract

The aim of this study was to evaluate whether the platelet-to-lymphocyte ratio (PLR) could be used to predict the prognosis of patients with nasopharyngeal carcinoma (NPC). Patients (n = 1261) who were diagnosed with nonmetastatic NPC between January 2008 and December 2010 were recruited. The peripheral platelet and lymphocyte counts were retrieved, and the PLR was calculated. Univariate and multivariate Cox proportional hazards analyses were used to assess their association with PLR: overall survival (OS), cancer-specific survival (CSS), and distant metastasis-free survival (DMFS). The elevated PLR, using the third quartile values (153.64) as the optimal cutoff values, was found to be associated with the significant decline in CSS (hazard ratio [HR] 1.83, 95 % confidence interval [CI] 1.27–2.63, P < 0.001), OS (HR 1.81, 95 % CI 1.28–2.56, P < 0.001), and DMFS (HR 1.60, 95 % CI 1.15–2.23, P = 0.005) that remained significant during the multivariable analyses (CCS HR 1.84, 95 % CI 1.26–2.67, P < 0.001; OS HR 1.83, 95 % CI 1.28–2.61, P < 0.001; DMFS HR 1.56, 95 % CI 1.11–2.19, P = 0.011). Subgroup analyses indicated that the PLR could be used to stratify prognosis effectively for patients with early- or advanced-stage NPC, and Epstein–Barr virus DNA levels of ≥1500 copies/mL. In conclusions, elevated PLR values were associated with poor CSS, OS, and DMFS for patients with NPC; this easily accessed variable based on a large amount of cases multivariate analysis is valuable for predicting prognosis in patients with NPC.

Keywords

Nasopharyngeal carcinoma Platelet-to-lymphocyte ratio Overall survival Cancer-specific survival Distant metastasis-free survival Prognosis 

Notes

Acknowledgments

This work was supported by grants from the Program for Sun Yat-Sen University Clinical Research 5010 Program (No.201310), New Century Excellent Talents in University (NCET-12-0562), and Guangdong Provincial Natural Science Foundation of China (S2013020012726) (to M.Y. Chen).

Conflicts of interest

None

References

  1. 1.
    Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. 2012;31:185–96.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011;30:114–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a “Cantonese cancer”? Chin J Cancer. 2010;29:517–26.CrossRefPubMedGoogle Scholar
  4. 4.
    Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: npc-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005;23:6966–75.CrossRefPubMedGoogle Scholar
  5. 5.
    Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol. 2005;23:1118–24.CrossRefPubMedGoogle Scholar
  6. 6.
    Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5:845–56.CrossRefPubMedGoogle Scholar
  7. 7.
    Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041–54.CrossRefPubMedGoogle Scholar
  8. 8.
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.CrossRefPubMedGoogle Scholar
  9. 9.
    McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12:223–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197:466–72.CrossRefPubMedGoogle Scholar
  11. 11.
    Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol. 2011;13:499–503.CrossRefPubMedGoogle Scholar
  12. 12.
    Krenn-Pilko S, Langsenlehner U, Thurner EM, Stojakovic T, Pichler M, Gerger A, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer. 2014;110:2524–30.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, et al. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin a/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer. 2004;100:1162–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, Li JY, et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IGA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer. 1985;36:545–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Ma J, Liu L, Tang L, Zong J, Lin A, Lu T, et al. Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: prognostic value and staging categories. Clin Cancer Res. 2007;13:1445–52.CrossRefPubMedGoogle Scholar
  16. 16.
    Chen L, Mao YP, Xie FY, Liu LZ, Sun Y, Tian L, et al. The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. Radiother Oncol. 2012;104:331–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350:2461–70.CrossRefPubMedGoogle Scholar
  18. 18.
    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.CrossRefPubMedGoogle Scholar
  20. 20.
    Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073–81.CrossRefPubMedGoogle Scholar
  21. 21.
    Kuter DJ. Milestones in understanding platelet production: a historical overview. Br J Haematol. 2014;165:248–58.CrossRefPubMedGoogle Scholar
  22. 22.
    Hwang SG, Kim KM, Cheong JH, Kim HI, An JY, Hyung WJ, et al. Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol. 2012;38:562–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Hernandez E, Donohue KA, Anderson LL, Heller PB, Stehman FB. The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2000;78:137–42.CrossRefPubMedGoogle Scholar
  24. 24.
    Suzuki K, Aiura K, Kitagou M, Hoshimoto S, Takahashi S, Ueda M, et al. Platelets counts closely correlate with the disease-free survival interval of pancreatic cancer patients. Hepatogastroenterology. 2004;51:847–53.PubMedGoogle Scholar
  25. 25.
    Gao J, Zhang HY, Xia YF. Increased platelet count is an indicator of metastasis in patients with nasopharyngeal carcinoma. Tumour Biol. 2013;34:39–45.CrossRefPubMedGoogle Scholar
  26. 26.
    Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res. 2002;22:913–22.CrossRefPubMedGoogle Scholar
  27. 27.
    Garraud O, Cognasse F. Are platelets cells? And if yes, are they immune cells? Front Immunol. 2015;6:70.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Egan K, Crowley D, Smyth P, O’Toole S, Spillane C, Martin C, et al. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS One. 2011;6, e26125.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kono SA, Heasley LE, Doebele RC, Camidge DR. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets. 2012;12:107–23.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas. 2006;32:22–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137:425–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Rabinowich H, Cohen R, Bruderman I, Steiner Z, Klajman A. Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res. 1987;47:173–7.PubMedGoogle Scholar
  33. 33.
    Dworacki G, Meidenbauer N, Kuss I, Hoffmann TK, Gooding W, Lotze M, et al. Decreased zeta chain expression and apoptosis in CD3+ peripheral blood t lymphocytes of patients with melanoma. Clin Cancer Res. 2001;7:947s–57.PubMedGoogle Scholar
  34. 34.
    Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 2012;91:167–81.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim KH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer. 2013;13:350.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13:633–41.CrossRefPubMedGoogle Scholar
  38. 38.
    Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, et al. Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival. J Clin Oncol. 2011;29:4516–25.CrossRefPubMedGoogle Scholar
  39. 39.
    Song C, Yang S. A meta-analysis on the EBV DNA and VCA-IGA in diagnosis of nasopharyngeal carcinoma. Pak J Med Sci. 2013;29:885–90.PubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Rou Jiang
    • 1
    • 2
    • 3
  • Xiong Zou
    • 1
    • 3
  • Wen Hu
    • 1
    • 3
  • Yu-Ying Fan
    • 1
    • 3
  • Yue Yan
    • 2
    • 3
  • Meng-Xia Zhang
    • 1
    • 3
  • Rui You
    • 1
    • 3
  • Rui Sun
    • 1
    • 3
  • Dong-Hua Luo
    • 1
    • 3
  • Qiu-Yan Chen
    • 1
    • 3
  • Pei-Yu Huang
    • 1
    • 3
  • Yi-Jun Hua
    • 1
    • 3
  • Ling Guo
    • 1
    • 3
  • Ming-Yuan Chen
    • 1
    • 3
  1. 1.Department of Nasopharyngeal CarcinomaSun Yat-sen University Cancer CenterGuangzhouChina
  2. 2.Department of Cancer PreventionSun Yat-sen University Cancer CenterGuangzhouChina
  3. 3.Collaborative Innovation Center of Cancer Medicine, State Key Laboratory of Oncology in South ChinaSun Yat-sen University Cancer CenterGuangzhouChina

Personalised recommendations